ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen: FDA Letter Rejects Expanded Use Of Xgeva For Prostate Cancer

DOW JONES NEWSWIRES Amgen Inc. (AMGN) received a complete response letter from the U.S. Food and Drug Administration rejecting the expanded use of Xgeva in men with prostate cancer that hasn't spread to the bones. According to the drug maker, the FDA letter said the agency can't approve the supplemental biologics license application in its present form because the effect on bone metastases-free survival doesn't outweigh the risks, such as osteonecrosis of the jaw, a rare jaw-decay problem. "We are reviewing the complete response letter and will work with FDA to determine any next steps," said Sean E. Harper, executive vice president of research and development. Xgeva is currently approved to delay fractures and other bone injuries in patients whose cancer has already spread to the bones. It is also sold under the brand name Prolia as an osteoporosis treatment, but is administered at a lower dose. Xgeva's and Prolia's combined sales in 2011 topped $550 million. A federal advisory panel in February rejected Amgen's proposal to expand the bone drug's use, saying it was unclear whether the results were clinically meaningful. Amgen's study of Xgeva in men with prostate cancer that hadn't responded to previous therapies, but hadn't yet spread to the bones showed the drug prolonged median bone metastatis-free survival by 4.2 months. Shares closed Thursday at $70.79 and were inactive premarket. The stock it up 10% so far this year. -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
04/18/201511:04:02The 3 Best Stocks for Investing in Cholesterol Drugs
04/16/201516:05:00Amgen Announces Webcast Of 2015 First Quarter Financial Results
04/16/201507:34:40Amgen's "Overweight" Rating Reiterated at Piper Jaffray (AMGN)
04/15/201519:52:41Correction to Corlanor Article
04/15/201518:40:08FDA Approves Amgen's Heart-Failure Drug Corlanor -- Update
04/15/201518:31:09FDA Approves Amgen's Heart-Failure Drug Corlanor
04/15/201518:25:44FDA Approves Amgen's Heart-Failure Drug Corlanor
04/15/201517:04:00FDA Approves Corlanor® (ivabradine) To Reduce The Risk Of Hospitalization...
04/15/201508:59:033 Biotech Stocks That May Disappear Before 2020
04/13/201516:06:44Additional Proxy Soliciting Materials (definitive) (defa14a)
04/13/201510:42:08Radius Health: Flying Under The Radar With An Exceptional Pipeline
04/11/201515:02:0310 Largest Companies by Market Cap in Biotech
04/11/201514:02:03How Amgen Could Side-Step The Sting of Patent Expiration
04/11/201503:51:07Immunotherapy: Unleashing The Immune System To Decimate Cancer
04/09/201517:59:09Why Investors Shouldn't Worry About Explosive New Drug Pricing:...
04/08/201513:19:07Chasing - And Surviving - Today's Income Storm
04/06/201508:01:17Could Celgene Corporation Muscle Its Way Past Amgen Inc.?
04/06/201507:20:30Expanded indication for Amgen's Vectibix cleared in Europe
04/06/201505:00:00European Commission Approves Amgen's Vectibix® (panitumumab...
04/05/201509:52:02Can This Pharma Go From Good to Great?

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad